NCT02250885

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Gabrail Cancer Center Research · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Detailed description

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors in adult patients age \>/= to 18.

Conditions

• Carcinoma, Neuroendocrine

Interventions

Type	Name	Description
DRUG	Selinexor	Selective Inhibitor fo Nuclear Export (SINE)

Timeline

• Start date: 2014-08-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2014-09-26
• Last updated: 2019-09-17

Locations

1 site across 1 country: United States